Leadership

Chris Tompkins

Christopher Tompkins Ph.D., Chief Executive Officer

In addition to being the Chief Executive Officer, Chris Tompkins is a member of the Board of Directors. He has twenty years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations and the commercialization of new technologies. Dr. Tompkins past experience includes COO at Evia Medical, Vice President of Operations and Chief Compliance Officer at Atrius Bioscience, General Manager of Proligo LLC, and other executive roles at Proligo. Dr. Tompkins has also lead projects and performed engineering development for two marketed pharmaceutical products; at NeXstar Pharmaceuticals, he led the development team and designed the reactor technology for the macular degeneration treatment, Macugen™; and at Hoffmann-La Roche he was jointly responsible for the development and scale-up of the 5-FU pro-drug Xeloda™.  Dr. Tompkins graduated with a Bachelor of Science degree in Chemical Engineering from the University of Michigan and a Ph.D. in Chemical Engineering from North Carolina State University.

Gretchen Pratt

Gretchen Pratt, Sr. Director of Operations

Prior to joining KromaTiD, Ms. Pratt spent 9 years at Amgen in a variety of roles within Operations, including manufacturing, engineering, project management, and risk management. She has previous roles as Operations Manager at AlloSource, and Sr. Manager Primers & Probes at Proligo. Ms. Pratt has a B.A. in Chemistry from Kalamazoo College, M.S. in Chemical Engineering from the University of Virginia, and is a Certified Lean Six Sigma Green Belt (ASQ).

David Sebesta Ph.D., Chief Commercial Officer

He has twenty three years of pharmaceutical and biotechnology industry experience in the areas of synthetic chemistry; carbohydrate, nucleoside and oligonucleotide chemical process development; multidisciplinary R&D management; the commercialization of new technologies; and CMO-sector sales and business development. He was previously Director, Strategic Accounts, at Catalent Pharma Solutions; CEO of MBC Pharma, Founder and Principal consultant of the Prescient Group LLC; COO of BST, Inc.; and Director, R&D of Proligo LLC. Dr. Sebesta also taught undergraduate- and graduate-level organic chemistry as a Lecturer in the University of Colorado, Department of Chemistry and Biochemistry. Dr. Sebesta has a B.S. in Biochemistry from the University of New Mexico, a Ph.D. in Chemistry from Indiana University and was a NIH Post-doctoral Fellow at the University of Colorado.

Gordon Link

Gordon H. Link Jr. CPA, Chief Financial Officer

Mr. Link joined KromaTiD in 2018. After seven years in public accounting he served an additional 25 years in a variety of senior executive and senior financial roles in public and private biotech companies. Most recently Mr. Link served six years as the Chief Financial Officer of Newlink Genetics Corporation, completing a variety of financings including the Company’s Initial Public Offering. Previously, Mr. Link worked for Tapestry Pharmaceuticals, Inc., directing a staff of five to ten individuals in areas of accounting, risk management, financial reporting and investor relations. Mr. Link also worked with Tapestry’s Board of Directors to coordinate Tapestry’s initial public offering and subsequent follow-on public offerings of common stock. Prior to joining Tapestry, Mr. Link served as Corporate Controller of Synergen, Inc., Treasurer of the Syntex-Synergen Neuroscience Joint Venture, Treasurer of Synergen Development Corporation and Audit Manager with Deloitte & Touche USA LLP. Mr. Link received a B.S. degree in Chemistry from Rensselaer Polytechnic Institute and a B.A. degree in Accounting from Metropolitan State University

Board of Directors

Terry Opgenorth, Ph.D.

Serves as the Chairman of the Board of Directors. Dr. Opgenorth previously worked for Abbott Laboratories (now AbbVie) as Divisional Vice President of Metabolic Disease Research, Antiviral (HCV) Research and Target-Lead Discovery Research for Abbott’s Global Pharmaceutical Research and Development division. He also served as President and CEO of Vidasym for 6 years, a company developing drugs for human chronic kidney disease. Terry holds a number of current positions, including Vice President for CSU Ventures and Executive Director of LAUNCHPAD, CSO/Founder of VetDC, a veterinary oncology company, and Board of Directors for VetDC, UNeMed, PhotonPharma, and Laporte Therapeutics.  Dr. Opgenorth holds a B.A. in Biology from Calvin College and M.S. and Ph.D. degrees in Physiology from University of Illinois-Urbana.

Joel Bedford, Ph.D.

Dr. Bedford joined KromaTiD as a founder of the company in 2007, chairs the Scientific Advisory Board and is a member of the Board of Directors. Dr. Bedford is currently a Professor in the Department of Environmental and Radiological Health Sciences at Colorado State Universtiy and holds a joint faculty appointment in the University Graduate Program in Cell and Molecular Biology. His programs have been funded by NIH, DOE and NASA since 1966. He has served as a regular member and Chairperson of the NIH Radiation Study Section, as a Counselor, Associate Editor, and later as President of the Radiation Research Society. He has received various awards such as the Failla Award and the Excellence in Mentoring Award from the Radiation Research Society. He has been a regular member of the National Academies’ Board on Radiation Effects Research, and then on the National Academies’ Nuclear and Radiation Studies Board. He served a 5-year term on the Scientific Council of the Radiation Effects Research Foundation in Hiroshima, Japan, and is a member of the National Council on Radiation Protection and Measurements. Professor Bedford has authored 140 peer-reviewed articles, including several book chapters, and is an inventor on two patent applications. Professor Bedford received his B.A. degree in Chemistry from the University of Colorado, an M.S. degree in Radiology from the University of Colorado Medical School, and Doctor of Philosophy Degree in Radiobiology from Oxford University.

Nicholas Saccomono, Ph.D.

Dr. Saccomano joined the KromaTiD board in 2016. He has served as Chief Scientific Officer of Array BioPharma (Boulder, CO) since May 2014. Dr. Saccomano is a seasoned leader with 30 years of experience in pharmaceutical and biotechnology research and development, with expertise in discovery research, clinical development, portfolio strategy, technology and clinical candidate licensing, and scientific partnering. Dr. Saccomano previously was CTO at SomaLogic, Inc. and before that CSO at Bend Research Inc. Prior to Bend Research, held positions of increasing responsibility at Pfizer, Inc., including Senior VP in R&D and VP of Discovery Technology, where he managed and developed enabling technologies used broadly across the drug discovery pipeline. During his tenure, he also directed medicinal sciences, drug discovery and strategic alliances. Dr. Saccomano obtained his Ph.D. in chemistry from Columbia University.

Ginny Orndorff

Ginny Orndoff joined the KromaTiD board in 2015. She is the Executive Director of the Colorado Institute for Drug, Device, and Diagnostic Development (CID4) and acting CEO of SixOne Solutions, LLC, and Claudin Technologies. Ginny co-founded Evolutionary Genomics of Longmont, CO and was its CEO for 10 years, continuing today on its board of directors. Prior to that, she was CEO of GenoPlex of Denver, CO; Director of Technology/Business Development for NeXstar of Boulder, CO; and Director of Biotechnology Programs at the Colorado Advanced Technology Institute. She has a B.A. in Biology from the University of California Santa Cruz, an M.A. in Microbiology from California State University San Jose, and an M.B.A from Loyola College.

Christopher Tompkins, Ph.D.

Chris Tompkins is the Chief Executive Officer and is a member of the Board of Directors. He has twenty years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations and the commercialization of new technologies. Dr. Tompkins past experience includes COO at Evia Medical, Vice President of Operations and Chief Compliance Officer at Atrius Bioscience, General Manager of Proligo LLC, and other executive roles at Proligo. Dr. Tompkins has also lead projects and performed engineering development for two marketed pharmaceutical products; at NeXstar Pharmaceuticals, he led the development team and designed the reactor technology for the macular degeneration treatment, Macugen™; and at Hoffmann-La Roche he was jointly responsible for the development and scale-up of the 5-FU pro-drug Xeloda™.  Dr. Tompkins graduated with a Bachelor of Science degree in Chemical Engineering from the University of Michigan and a Ph.D. in Chemical Engineering from North Carolina State University.